PEDIATRICS Vol. 39 No. 3 March 1967, pp. 363-371
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stokes, J.
Right arrow Articles by Hilleman, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stokes, J., Jr.
Right arrow Articles by Hilleman, M. R.

LIVE ATTENUATED MUMPS VIRUS VACCINE. II. EARLY CLINICAL STUDIES

Joseph Stokes Jr. M.D.1, Robert E. Weibel M.D.1, Eugene B. Buynak Ph.D.1, and Maurice R. Hilleman Ph.D.1

1 Department of Pediatrics, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, and Division of Virus and Cell Biology Research, Merck Institute for Therapeutic Research, West Point, Pennsylvania

Groups of children in institutions who were initially without mumps antibody were inoculated subcutaneously with twelfth chick embryo and chick embryo cell culture passage (level A) or seventeenth passage (level B) Jeryl Lynn strain mumps virus vaccine. All children developed mumps antibody following inoculation of either strain. The level A vaccine, however, was insufficiently attenuated for routine immunization, since roughly 25% of the vaccine recipients developed parotitis and excreted mumps virus. Children who received B level virus failed to develop fever or parotitis or any other significant clinical reaction to the vaccine and serum amylase values were not significantly altered. Mumps neutralizing antibody persisted for at least 7 months following vaccine B, the longest period tested. A study among children in a community showed that as little as 317 50% tissue culture infectivity doses of virus in level B vaccine induced neutralizing antibody in 100% of children vaccinated. The B level vaccine proved entirely safe and highly effective in inducing protective antibody against mumps.

Submitted on July 29, 1966
Accepted on October 14, 1966